Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
Priority
Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55.
Election/Restrictions
Claims 10-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/03/2026.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1 and 5-7 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Bjerregaard (WO-20180773610).
Regarding claim 1, Bjerregaard teaches:
A process for manufacturing an enema nozzle ([0067]; Fig. 1, #1) comprising an insertion body ([0067] – [0069]; Fig. 1, #2 and #3) and a flexible insertion tip ([0067] – [0068]; Fig. 1, #4), wherein said enema nozzle is manufactured in a single injection molding procedure by 2K injection molding or 3K injection molding ([0040] and [0061] – [0063]).
Regarding claim 5, Bjerregaard the limitations of claim 1, which claim 5 depends on. Bjerregaard further teaches:
wherein the single injection molding procedure is performed on one machine that is programmed to perform the injection of the polymers in a single cycle ([0061]).
Regarding claim 6, Bjerregaard the limitations of claim 1, which claim 6 depends on. Bjerregaard further teaches:
wherein the single injection molding procedure is a co-injection molding process, a sequential injection molding process, or an overmolding injection process ([0040] and [0061] – [0063]).
Regarding claim 7, Bjerregaard the limitations of claim 1, which claim 7 depends on. Bjerregaard further teaches:
wherein a hydrophilic coating is applied to the flexible insertion tip, and optionally at least the part of the insertion body intended for being inserted into the body opening ([0036] and [0074]).
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim 8 is rejected under 35 U.S.C. 103 as being unpatentable over Bjerregaard (WO-20180773610), as applied to claim 7 above.
Regarding claim 8, Bjerregaard teaches the limitations of claim 7, which claim 8 depends on. Bjerregaard further teaches:
wherein the enema nozzle is prepared via the 3K injection molding in which the flexible insertion tip and the insertion body is first formed in the 2K injection molding, and the hydrophilic coating is applied using overmolding. Bjerregaard teaches preparing the enema nozzle with a 2k or 3k injection molding process ([0040] and [0061] – [0062]), and teaches applying a hydrophilic surface coating to the enema ([0036] and [0074]). Overmolding is commonly known in the art as a method of applying a polymer coating surface layer on top of another polymer layer, therefore it would be obvious to one of ordinary skill in the art in the absence of a showing of unexpected results to use overmolding in order to apply the hydrophilic coating on to the enema being made.
Claims 2-4 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over Bjerregaard (WO-20180773610), as applied to claim 1 above, and further in view of Jonsman (WO-2018233793) and Lee (US-20160310715).
Regarding claim 2, Bjerregaard teaches the limitations of claim 1, which claim 2 depends on, but does not explicitly teach the single injection molding procedure combining a polymer having intrinsic hydrophilic properties with one or two elastomeric polymer(s). However, Jonsman, in a similar field of endeavor, the use of a polymer with intrinsic hydrophilic properties for injection molding, teaches:
wherein the single injection molding procedure uses a polymer having intrinsic hydrophilic properties ([0003] and [0026]).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the single injection molding procedure of Bjerregaard to incorporate the teachings of Jonsman and use a polymer having intrinsic hydrophilic properties. The purpose, as stated by Jonsman, being that it is well known to compound different polymers having different material properties together thereby producing blended polymers or compound polymers with intermediate properties that are all needed in the resulting compound polymer material ([0026]).
Bjerregaard in view of Jonsman does not explicitly teach:
the hydrophilic polymer being combined with one or two elastomeric polymer(s), respectively.
However, Lee, in a similar field of endeavor, the process of manufacturing a drug delivery device using injection molding of hydrophilic polymers, teaches:
the hydrophilic polymer being combined with one or two elastomeric polymer(s), respectively ([0072] and [0114]).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the single injection molding procedure of Bjerregaard in view of Jonsman to incorporate the teachings of Lee and combine the hydrophilic polymer with an elastomeric polymer. The purpose, as stated by Lee, being that it can be advantageous to utilize a combination of two different polymeric materials, rather than making the device entirely of the water-swelling hydrophilic, drug-permeable second material, to achieve desired mechanical properties ([0077]).
Regarding claim 3, Bjerregaard in view of Jonsman and Lee teaches the limitations of claim 2, which claim 3 depends on. Bjerregaard further teaches:
wherein the polymer having intrinsic hydrophilic properties is used to form the flexible insertion tip. It would be obvious to one of ordinary skill in the art to use the hydrophilic polymer for whatever part is needed when looking at the combination of Bjerregaard in view of Jonsman and Lee made in claim 2 above.
Regarding claim 4, Bjerregaard in view of Jonsman and Lee teaches the limitations of claim 2, which claim 4 depends on. Bjerregaard further teaches:
wherein the polymer having intrinsic hydrophilic properties is used to form the part of the insertion body intended for being inserted into the body opening. It would be obvious to one of ordinary skill in the art to use the hydrophilic polymer for whatever part is needed when looking at the combination of Bjerregaard in view of Jonsman and Lee made in claim 2 above.
Regarding claim 9, Bjerregaard in view of Jonsman and Lee teaches the limitations of claim 2, which claim 9 depends on. Bjerregaard further teaches:
wherein the elastomeric polymers are selected from the group consisting of thermoplastic elastomers (TPE), polyurethane (PU), polyethylene (PE), polyvinyl chloride (PVC), silicone ([0040] and [0062] – [0063]), styrene ethylene butylene styrene (SEBS), thermoplastic polyester elastomer (TPC), and thermoplastic styrenic elastomer (TPS).
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Adrien J Bernard whose telephone number is (571)272-1384. The examiner can normally be reached M-R, from 7:30a.m.-4:30p.m..
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alison L Hindenlang can be reached at 571 270-7001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/A.B./Examiner, Art Unit 1741 /JACOB T MINSKEY/Primary Examiner, Art Unit 1748